Home › Liver Cancer (Hepatocellular Carcinoma) › NCT07019844

PSMA PET for the Staging and Management of Hepatocellular Carcinoma

Addition of F18-Piflufolastat PET/CT to Cross-Sectional Imaging for the Staging and Management of Hepatocellular Carcinoma

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adult patients age \>18 years from the VA medical system
* Treatment-naïve patients with HCC with BCLC B or C disease

Exclusion Criteria:

* Patients with renal dysfunction or contrast allergy that precludes contrast enhanced cross sectional imaging
* Patients with presence of active primary malignancy other than HCC and non-melanoma skin cancer in the past 3 years

About the study

This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.

Sponsor: VA Office of Research and Development · Participants: 90 · Started: Sep 19, 2024

Contact the study team

• Binu V John, MD MPH · Phone: (305) 575-7000
• Flavia R Carneiro, PhD · Phone: (305) 575-7762

Official record on ClinicalTrials.gov — NCT07019844

Locations in the U.S.

Conditions

• Liver Cancer (Hepatocellular Carcinoma)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.